Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
| Current Price | ₹1,362.10 |
|---|---|
| Market Cap | ₹18,874 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 30.1 |
| Return on Equity | 18.07% |
| 52-Week Range | ₹1,200.00 – ₹1,910.00 |
| Beta (1Y) | 0.04 |
| Dividend Yield | 1.06% |
1. Pharmaceuticals-100%
Eris Lifesciences Ltd is trading at ₹1,362.10, with a market capitalisation of ₹18,874 Cr.
Eris Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Eris Lifesciences Ltd has a P/E of 30.1 and a return on equity of 18.07%.